Your browser doesn't support javascript.
loading
Observation of effect of sequential therapy of butylphthalide for acute cerebral infarction and its influence on plasma lipoprotein phospholipase A2 / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy ; (12): 1289-1292, 2017.
Article in Chinese | WPRIM | ID: wpr-512901
ABSTRACT
Objective To observe the effect of sequential therapy of butylphthalide injection and soft capsules for acute cerebral infarction and its influence on plasma lipoprotein phospholipase A2.Methods 120 patients with cerebral infarction were selected in the study,and they were divided into observation group (64 cases) and control group(56 cases) according to the digital table.The control group received conventional therapy plus placebo,the observation group received the sequential administration of butylphthalide injection and butylphthalide soft capsule treatment based on the conventional treatment.Before and after treatment,the plasma lipoprotein phospholipase A2 of the two groups was detected,and the National Institutes of Health Stroke Scale (NIHSS) was evaluated,compared neurological deficit improvement between the two groups and recorded adverse drug reactions of the two groups.Results There were no significant differences in NIHSS score and plasma lipoprotein phospholipase A2 level between the two groups before treatment(all P > 0.05).After treatment,the NIHSS score of neurological impairment,plasma lipoprotein phospholipase A2 level in the observation group were (6.40 ± 5.22) points,(203.26 ± 29.33) ng/mL,those in the control group were (8.59 ± 6.22) points,(253.10 ± 52.99) ng/mL,the differences were statistically significant(t =-1.36,-2.089,P =0.039,0.000).The total effective rate of the observation group was 90.6%,which was higher than 67.9% of the control group,the difference was statistically significant (x2 =9.676,P =0.002).The incidence rate of adverse reactions was similar in the two groups (P > 0.05).Conclusion Sequential therapy of butylphthalide for acute cerebral infarction can improve the neurological function,decrease the level of plasma lipoprotein phospholipase A2,inhibit the inflammation of blood vessels,improve the prognosis of patients.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Controlled clinical trial Language: Chinese Journal: Chinese Journal of Primary Medicine and Pharmacy Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Controlled clinical trial Language: Chinese Journal: Chinese Journal of Primary Medicine and Pharmacy Year: 2017 Type: Article